No Data
No Data
Countdown to Alcon (ALC) Q2 Earnings: Wall Street Forecasts for Key Metrics
Needham Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $101
Spencer Trask & Co. Launches Dry Eye Venture Signal12 With Former Aerie Pharmaceutical Executives Thomas Mitro and Marvin Garrett
OcuMension Agrees To Acquire Rights Of Alcon Eye Drops In Exchange For 16.7% Equity Stake
Eucon and Alcon have initiated a comprehensive strategic cooperation. Eucon will have the rights to 8 Alcon products for dry eye conditions in China, while Alcon will hold a 16.7% stake in Eucon.
Shanghai, China – On August 13, 2024, Ocumension Therapeutics (referred to as "Ocumension") announced an agreement with Alcon Inc. (referred to as "Alcon", together with Ocumension referred to as the "Parties"), whereby Ocumension will gain the rights to Alcon's portfolio of 8 dry eye treatment and surgical eye drop products in China, including 7 mature products that are already on the market and one product that is in clinical development stage. The agreement will also cover the areas of research and development, manufacturing and commercialization in China. In connection with the transfer of these rights, Ocumension will issue 139,159,664 shares to Alcon.
Nasdaq, S&P 500 Futures Climb After Volatile Week As Traders Eye Inflation Data and Retail Earnings: Strategist Says Not CPI But This Data Can Give People Lot Of Conviction
No Data
103480872 : congrats
sentosa island : Alco is good